Increasing the understanding of the molecular and cellular players involved in the regulation of adult skeletal muscle mass is an important open issue in current muscle biology. Muscle mass is regulated through a delicate balance between protein synthesis and protein breakdown. Under conditions of muscle hypertrophy, protein synthesis exceeds protein breakdown, resulting in an increase in the size of individual muscle fibers. In the last 20 years the key intracellular signaling pathways regulating muscle mass have been elucidated, showing an important role for IGF1-Akt-mTORC1 and Myostatin-BMP signaling in the regulation of adult skeletal muscle mass [1] . Although the intracellular signaling pathways that regulate size of muscle fibers are being unraveled, the contribution of other cell types to muscle cell growth is a more debated issue.
In addition to muscle fibers, various muscle-resident cell types, like satellite cells, pericytes, and Fibro/Adipogenic Progenitors (FAPs), contribute to the maintenance, growth, and regeneration of adult skeletal muscle.
Satellite cells are the best described muscle-resident cell type, and, when activated, they can proliferate and fuse to the growing fiber, thereby increasing the number of myonuclei. Satellite cells are absolutely necessary for skeletal muscle to form or to regenerate new myofibers. However, their contribution to adult muscle hypertrophy is less clear [2] . The most common hypothesis has been that for muscle fibers to maintain bigger dimensions, additional nuclei need to be added to the growing fibers, thereby preventing the myonuclear domain from becoming too big. Experimentally, the role of satellite cells in muscle hypertrophy was addressed some years ago using a transgenic mouse model, in which satellite cells were ablated from adult skeletal muscle. When overloading the plantaris muscle from these mice by synergist ablation, no impairment of the hypertrophic response was observed [3] . Furthermore, transgenic activation of Akt, or inhibition of myostatin signaling leads to muscle growth without addition of new myonuclei [4, 5] . Recently, however, it was shown that muscles lacking satellite cells do not undergo fiber hypertrophy, suggesting an important role for these muscle stem cells also in the growth response [6] .
Although it is not straightforward to reconcile these completely opposite results, satellite cell activation is likely to have a role in proper muscle remodeling during an intense stimulus, such as synergist ablation. Indeed, when examining muscle remodeling in satellite cell-depleted muscles at later time points after synergist ablation, there was a significant increase in muscle fibrosis and an impairment of muscle function [7] . Interestingly, this requirement for satellite cells in proper long-term muscle remodeling is due to their role in preventing muscle fibrosis generated by fibrogenic cells present in skeletal muscle [8] . It was proposed that this communication occurs through exosomes released from activated satellite cells. These results suggest an important interaction between satellite cells and other muscle-resident cells in generating a proper muscle remodeling during hypertrophy.
In line with this suggested role of other cells playing a role in muscle hypertrophy, a recent study published in FEBS Letters by Sugg et al. showed that treatment of mice with an inhibitor of Platelet-Derived Growth Factor Receptor (PDGFR) completely prevents overload-induced muscle hypertrophy [9] . In overloaded muscles of inhibitor-treated mice the typical activation of Akt-S6K1 signaling and increase in transcription of extracellular matrix markers was strongly reduced, supporting the hypothesis that PDGFR inhibition compromised the hypertrophic response. PDGFR alpha is predominantly expressed in muscle-resident FAPs, which are located into the interstitial space between myofibers close to vessels [10] . PDGFR beta on the other hand is mainly localized on pericytes and PW1-positive interstitial cells in skeletal muscle. The inhibitor used by Sugg et al. cannot be used to Abbreviations FAPs, Fibro/Adipogenic Progenitors; IGF1, insulin-like growth factor 1; PDGFR, Platelet-Derived Growth Factor Receptor. discriminate between PDGFR alpha or PDGFR beta signaling. However, it is unlikely that the inhibition of muscle hypertrophy is due to inhibition of PDGFR alpha signaling, as the latter has been associated with a reduction in fibrosis, and would probably be beneficial to muscle growth.
It is more likely that PDGFR beta signaling promotes muscle growth, as both pericytes and PW1-positive interstitial cells can contribute to the myogenic response during regeneration. In particular, pericytes are potentially important for muscle growth, as it was shown that ablation of muscle pericytes reduces postnatal muscle growth, possibly by acting on the activation of satellite cells [11] . Interestingly, activation of pericytes during postnatal growth is accompanied by increased production of insulin-like growth factor 1 (IGF1). Deletion of pericyte-released IGF1 is actually sufficient to phenocopy the reduced postnatal growth response seen in pericyte-ablated muscles, and this suggests that IGF1 may act directly or indirectly on muscle fibers to promote the growth response. These results make it tempting to speculate that the reduced Akt-S6K1 signaling observed by Sugg et al. in the absence of PDGFR signaling could be due to an inhibition of IGF1 release by pericytes. It would be very interesting to understand if released IGF1 acts through the activation of satellite cells or if they influence directly the muscle fibers. In a very recent paper, it was shown that satellite cell-specific deletion of Myomaker, a critical regulator of myoblast fusion, is required to induce satellite cell fusion to myofibers during overload hypertrophy [12] . Interestingly, this reduction in Myomaker is sufficient to reduce Akt-S6K1 signaling and the hypertrophic response in myofibers. As Sugg et al. report a significant reduction in Myomaker upon PDGFR inhibition, it is tempting to assume that the events downstream of PDGFR signaling involve activation of satellite cells in order to effect the growth of muscle fibers.
Even though the role of other muscle cell types in muscle growth is slowly being elucidated, the role they play in muscle function is still a completely open issue. In the study by Sugg et al., the effect of PDGFR inhibition on the function of the overloaded muscles was not assessed. Although no effect was observed on muscle mass, gene expression analyses show that a major transcriptional response occurs in these muscles, and this finding is suggestive of a significant muscle remodeling. This additional data would be very helpful not only for defining the signaling pathways involved in the regulation of muscle mass but also for understanding what pathways regulate muscle force production. Despite the important implications of elucidating how muscle function can be improved, the signaling pathways required for increasing muscle force, which do not necessarily overlap with the signaling pathways that regulate muscle mass, are only starting to be unraveled. For example, a recent study has shown that although hypertrophy can occur in the absence of the key mediator of protein synthesis S6K1, S6K1 is absolutely required for increasing muscle force during hypertrophy [13] .
Overall, this new study by Sugg et al. spans from elucidating a role for PDGFR signaling in muscle growth to highlighting the important contribution of nonmuscle cells to such a response. But still several related issues remain open. Is the interplay between different muscle-resident cell types important in maintaining muscle structure and function during hypertrophy? Does a reduction in new vessel formation during muscle growth also affect muscle force production? All interesting and open questions which surely will start to be unraveled in the upcoming years.
